From Peak to Plunge: A Multi-Database Analysis of State Level Disparities in Hydromorphone use in the U.S. (2010-2023)
Patel, K. S.; McCall, K. L.; Piper, B. J.
Show abstract
BackgroundHydromorphone is a semi-synthetic opioid agonist and a hydro-genated ketone of morphine. This study observed hydromorphone use in the United States (US) using three databases. Methods: The distribution of hydromorphone in the US (in grams) was provided by US Drug Enforcement Administrations Automated Reports and Consolidated Orders System (ARCOS) by state, zip code, and by business types (pharmacies, hospitals, providers, etc.). Hydromorphone prescriptions claims were also examined using the Medicaid and Medicare Part D programs from 2010 to 2023. Results: Hydromorphone increased by +30.6% by 2013, followed by a decrease of -55.9% by 2023 in ARCOS. Medicaid hydromorphone prescriptions increased +39.6% by 2015 and de-creased -48.9% by 2023. Medicare Part D hydromorphone claims increased +8.5% by 2015 and decreased -31.9% by 2023. There were also pronounced regional disparities in hydro-morphone use identified in ARCOS (158.7 fold), Medicaid (17.5 fold), and Medicare Part D (13.7 fold). Conclusions: Hydromorphone use in the US has decreased substantially from 2010 to 2023. Additionally, these findings highlight regional disparities in hydro-morphone use, which may inform targeted opioid stewardship initiatives and guide policymakers to ensure safe and equitable opioid prescribing practices.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimating The Uncertain Effect of the COVID Pandemic on Drug Overdoses 94%
- Opioid Overdose and Naloxone Administration Knowledge and Perceived Competency in A Probability Sample of Indiana Urban Communities with Large Black Populations 93%
- Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients 93%
Similar papers in this journal
- Pharmacoepidemiology of Oxycodone in the USA: an observational study of ARCOS, Medicaid, and Medicare drug databases 98%
- Declines, and Pronounced Regional Disparities, in Meperidine Use in the United States 98%
- Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug Class Dipeptidyl-Peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? 90%
Similar papers in this journal
- Sales of over-the-counter products containing codeine in 31 countries, 2013-2019: a retrospective observational study 93%
- Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media 93%
- Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center 92%
Similar papers in this journal
- Drug Overdose Mortality Rates by Educational Attainment and Sex for Adults Aged 25 to 64 in the United States Before and During the COVID-19 Pandemic, 2015 to 2021 95%
- Fentanyl, Heroin, and Methamphetamine-Based Counterfeit Pills Sold at Tourist-Oriented Pharmacies in Mexico: An Ethnographic and Drug Checking Study 94%
- Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020 to 2023 92%
Similar papers in this journal
- Trends and Patterns of Opioid Epidemic: A Large-Scale Retrospective Study of Hospital Visits with Opioid Poisoning in New York State, 2010-2016 94%
- Optimizing hospital opioid deprescribing: a multi-level consensus study bridging evidence, expertise, and patient perspectives 93%
- A Systematic review and Network Meta-analysis of pharmaceutical interventions used to manage chronic pain 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.